|
|
|
|
| LEADER |
04986nam a2200577 4500 |
| 001 |
on1018457778 |
| 003 |
OCoLC |
| 005 |
20200326101150.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
180111s2018 mau o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OCLCF
|d NLE
|d CNCGM
|d UPM
|d OCLCQ
|d N$T
|d INT
|d OCLCQ
|d UKMGB
|d GrThAP
|
| 015 |
|
|
|a GBB803852
|2 bnb
|
| 016 |
7 |
|
|a 018668623
|2 Uk
|
| 020 |
|
|
|a 9780128154243
|q (electronic bk.)
|
| 020 |
|
|
|a 0128154241
|q (electronic bk.)
|
| 020 |
|
|
|a 0128152060
|
| 020 |
|
|
|a 9780128152065
|
| 035 |
|
|
|a (OCoLC)1018457778
|
| 050 |
|
4 |
|a RB40
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.07/56
|2 23
|
| 245 |
0 |
0 |
|a Advances in clinical chemistry.
|n Volume 84 /
|c edited by Gregory S. Makowski.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2018.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Advances in Clinical Chemistry
|v Volume 84
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover; Advances in Clinical Chemistry; Copyright; Contents; Contributors; Preface; Chapter One: Protein Carbamylation: Chemistry, Pathophysiological Involvement, and Biomarkers; 1. Introduction; 2. The Carbamylation Reaction; 3. Impact of Carbamylation on Protein Properties; 3.1. Alteration of Structural Properties; 3.2. Loss of Function; 3.3. Impairment of Protein-Protein and Protein-Cell Interactions; 4. Protein Carbamylation in Aging and Diseases; 4.1. Aging; 4.2. Cataract; 4.3. Chronic Kidney Disease; 4.4. Atherosclerosis; 4.5. Rheumatoid Arthritis; 4.6. Neurological Disorders.
|
| 505 |
8 |
|
|a 5. Biomarkers of Protein Carbamylation5.1. Carbamylated Hemoglobin; 5.2. Carbamylated LDLs; 5.3. Free Carbamylated Amino Acids; 5.4. Carbamylated Albumin; 5.5. Homocitrulline; 6. Analytical Methods for the Measurement of CDPs; 6.1. Colorimetric Assay; 6.2. Immunoassay; 6.3. Chromatographic Methods; 6.4. HPLC-MS/MS; 6.5. Capillary Electrophoresis; 7. Conclusion; Conflict of Interest; References; Chapter Two: Inflammatory Response During Myocardial Infarction; 1. Introduction; 2. Inflammatory Phase; 2.1. Danger-Associated Molecular Patterns; 2.1.1. High-Mobility Group Box 1 Protein.
|
| 505 |
8 |
|
|a 2.1.2. Extracellular ATP2.1.3. Mitochondrial DNA; 2.1.4. Heat-Shock Proteins; 2.1.5. Fibronectin; 2.1.6. Calgranulins S100; 2.1.7. Extracellular RNA; 2.2. Pattern Recognition Receptors; 2.2.1. Toll-Like Receptors; 2.2.2. Receptor for Advanced Glycation End Product; 2.2.3. NOD-Like Receptors; 2.3. The Nuclear Factor Kappa B; 2.4. The Complement System; 2.5. Reactive Oxygen Species; 2.6. Cytokines; 2.6.1. TNF-É#x91;; 2.6.2. IL-1; 2.6.3. IL-6; 2.7. Chemokines; 2.8. Cellular Effectors; 2.8.1. Neutrophils; 2.8.2. Monocytes/Macrophages; 2.8.3. Cardiac Fibroblasts; 2.8.4. DCs and Lymphocytes.
|
| 505 |
8 |
|
|a 3. Proliferative Phase3.1. Inflammation Suppression; 3.1.1. Cellular Effectors; 3.1.2. Molecular Signaling; 3.2. Scar Formation and Fibrosis; 3.2.1. Fibroblast Spread and Transdifferentiation; 3.2.2. Extracellular Matrix Rearrangement; 4. Maturation Phase; 5. Cardiac Remodeling; 5.1. Early Cardiac Remodeling; 5.2. Late Cardiac Remodeling; 6. MI and Atherosclerosis: A Dual Path; 7. Conclusion; References; Chapter Three: Metabolomics of Major Depressive Disorder and Bipolar Disorder: Overview and Future Perspective; 1. Introduction; 2. MDD; 2.1. Blood Samples.
|
| 505 |
8 |
|
|a 2.2. Blood Biomarkers of Ketamine's Antidepressant Actions in Patients With MDD2.3. Urine Samples; 2.4. Cerebrospinal Fluid (CSF) Samples; 3. BD; 3.1. Postmortem Brain Samples; 3.2. Blood Samples; 3.3. Blood Biomarkers for Ketamine's Antidepressant Actions in Patients With BD; 3.4. Urine Samples; 3.5. CSF Samples; 4. Conclusion and Future Direction; Acknowledgment; Conflict of Interest; References; Chapter Four: Blood Glucose Determination: Effect of Tube Additives; 1. Introduction; 2. Literature Search; 3. Search Results; 3.1. Impact of Citrate Buffer on Glucose Concentration and Stability.
|
| 650 |
|
0 |
|a Clinical chemistry.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Clinical chemistry.
|2 fast
|0 (OCoLC)fst00864330
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Makowski, Gregory S.
|q (Gregory Stephen)
|
| 776 |
0 |
8 |
|i Print version:
|t Advances in clinical chemistry. Volume 84.
|d Cambridge, MA : Academic Press, 2018
|z 0128152060
|z 9780128152065
|w (OCoLC)1005122028
|
| 856 |
4 |
0 |
|3 ScienceDirect
|u https://www.sciencedirect.com/science/bookseries/00652423/84
|z Full Text via HEAL-Link
|
